www.fdanews.com/articles/138480-nktr-102-receives-positive-opinion-from-ema-comp-for-orphan-medicinal-product-designation-in-ovarian-cancer

NKTR-102 Receives Positive Opinion From EMA COMP for Orphan Medicinal Product Designation in Ovarian Cancer

July 18, 2011

Nektar Therapeutics announced that the European Medicines Agency Committee for Orphan Medicinal Products (COMP) has issued a positive opinion on its application for orphan medicinal product status for the company’s lead oncology candidate, NKTR-102, for the treatment of women with ovarian cancer.
MarketWatch